T-cell engagers (TCEs) are among the most promising new modalities in cancer therapy. However, their target repertoire has been restricted to tumor-associated antigens that are expressed on the cell surface. Accessing intracellular peptides displayed on MHC class I (pMHCs) would greatly expand the target pool for TCEs.

This case study showcases a potent, highly specific MAGE-A4 x CD3 TCE that is ready for further preclinical assessment. This molecule showed highly specific binding to MAGE-A4-pMHC and potent activity across multiple MAGE-A4-expressing cell lines. These data demonstrate how our TCE platform, combined with our antibody discovery capabilities, can generate highly specific TCEs for pMHC targets.